Bart Debrock, MD
Urology · Vincennes, INNPI 1538155890
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 153 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for urology clinicians in IN, where the typical reported total is $3,350.
Across 153 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$573
- Astellas Pharma US Inc$362
- Pfizer$306
- Sumitomo Pharma America, Inc.$281
- 180 Medical, Inc.$161
- Coloplast$155
- plus $742 from 24 others
What the payments were for
- Food & beverage$2,49597%
- Education$853%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 36 | $573 |
| Astellas Pharma US Inc | 25 | $362 |
| Pfizer | 18 | $306 |
| Sumitomo Pharma America, Inc. | 14 | $281 |
| 180 Medical, Inc. | 7 | $161 |
| Coloplast | 12 | $155 |
| AbbVie | 8 | $124 |
| C. R. Bard, Inc. & Subsidiaries | 5 | $92 |
| Tolmar, Inc. | 3 | $67 |
| BD | 2 | $41 |
| Teleflex LLC | 1 | $37 |
| Boston Scientific | 2 | $33 |
| Bayer | 2 | $33 |
| Olympus America Inc. | 2 | $31 |
| Amgen | 1 | $25 |
| Dendreon Pharmaceuticals LLC | 1 | $25 |
| Calyxo, Inc. | 1 | $23 |
| Immunitybio, Inc. | 1 | $21 |
| Myriad Genetic Laboratories, Inc. | 1 | $21 |
| Neotract Inc. | 1 | $20 |
| Novartis | 1 | $18 |
| Progenics Pharmaceuticals, Inc. | 1 | $17 |
| Duchesnay USA Incorporated | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
| Blue Earth Diagnostics | 1 | $15 |
| Photocure Inc | 1 | $14 |
| Urovant Sciences Inc | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
| Laborie Medical Technologies Corp. | 1 | $11 |
How this compares
$2,580 in reported general payments places this provider in the 40th percentile of 272 urology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 88 | $1,039 |
| Finasteride | 62 | $349 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 37 | $336 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 29 | $262 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 15 | $221 |
| Ciprofloxacin Hcl | 28 | $143 |
| Cephalexin | 33 | $112 |
| Levofloxacin | 16 | $63 |
Paid to pharmacies, not to this prescriber.
Other urology in Vincennes
- Alexander TatemCarmel$418K
- Chad ReichardCarmel$400K
- Michael BorofskyIndianapolis$244K
- Marcelino RiveraIndianapolis$171K
- Matthew MellonCarmel$159K
- James BailenJeffersonville$143K
- Greg SteinbockJeffersonville$134K
- Eugene ConeGreenwood$114K
- Jason KovacCarmel$112K
- Helen BernieIndianapolis$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.